IRVINE, Calif., Aug. 17, 2011 /PRNewswire/ — Endologix, Inc.
(Nasdaq:
ELGX), developer and marketer of minimally invasive treatments
for aortic disorders, announced today that Judge Tanya Walton Pratt
of the United States District Court for the Southern District of
Indiana in Indianapolis has issued a Markman ruling in the ongoing
patent infringement lawsuit filed against the Company by Cook
Medical.
In a Markman ruling, the court determines the meaning of
disputed patent claim terms at issue in patent litigation.
After a briefing and oral argument on April 15, 2011 as to
the meaning of a number of terms of the claims of the two patents
that Cook is asserting in the lawsuit, Judge Pratt adopted many of
Endologix’s proposed constructions for several terms of claims of
both asserted patents, including constructions that the Company
considers to be important for the outcome of the case.
The trial date for the patent infringement lawsuit has not yet
been set but is expected to be set for fall 2012.
John McDermott, President and Chief Executive Officer of
Endologix, commented, “We are pleased with the results of the
Markman hearing, remain confident in our position going forward and
intend to continue to pursue our numerous defenses.”
About Endologix, Inc.Endologix, Inc. develops and
manufactures minimally invasive treatments for aortic disorders.
The Company’s focus is endovascular stent grafts for the treatment
of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall
of the aorta, the largest artery in the body, resulting in a
balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix’s Web
‘/>”/>
